Osaka, Japan – March 12, 2025 – Atransen Pharma, Ltd. (Headquarters: Osaka, Japan; CEO: Tomoyuki Asano) is pleased to announce that its drug development candidate, APL1101, has been selected for the Strengthening Program for Pharmaceutical Startup Ecosystem by the Japan Agency for Medical Research and Development (AMED).
The selected program, “Development of Novel Anti-Cancer Drug by ‘Locking Inhibition’ of Amino Acid Transporter”, is aimed at accelerating the research and development of APL1101 as a novel anti-cancer therapy. APL1101 is an innovative drug development program targeting LAT1 (L-type amino acid transporter 1) with the potential to provide new treatment options for certain cancers and refractory diseases. With this selection, Atransen Pharma will accelerate its research and development efforts, advancing both preclinical and clinical development.
AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem aims to support the sustainable growth of Japanese pharmaceutical startups and foster the development of innovative medicines. The selection of APL1101 is a recognition of our ongoing research efforts and represents a significant milestone toward clinical development.Furthermore, this application and selection were made possible with the support of two certified venture capital (VC) firms, which have committed as lead and follow investors. These VC firms bring extensive expertise and a strong track record in the biotechnology and pharmaceutical sectors, making them key strategic partners for our future growth. Atransen Pharma is currently working closely with these investors to secure additional funding and strengthen our financial foundation for the next stage of APL1101’s development.
Atransen Pharma remains dedicated to its mission of addressing unmet medical needs through innovative drug discovery, aiming to improve patients’ quality of life. We will continue to advance APL1101 and our broader pipeline, striving to deliver new treatment options to patients worldwide.
About Atransen Pharma
Atransen Pharma is a pharmaceutical startup focused on developing novel therapeutics targeting LAT1. Leveraging cutting-edge technologies and scientific expertise, we aim to create groundbreaking treatments for cancer and refractory diseases.
Contact Information
Atransen Pharma, Ltd.
Email: admin@atransen.com
Website: www.atransen.com